{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:11:41Z","timestamp":1792239101260,"version":"4.4.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,30]]},"abstract":"<jats:p>Pan and colleagues report one of the first prospective evaluations of planned sequential chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and then CD22 in a phase 1 trial, indicating acceptable toxicity and encouraging durable efficacy in pediatric patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia (ALL).<\/jats:p>","DOI":"10.1182\/blood.2019003293","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T11:27:52Z","timestamp":1573730872000},"page":"387-391","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":154,"title":["Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-0336","authenticated-orcid":false,"given":"Jing","family":"Pan","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Zuo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[{"name":"Cytology Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Xu","sequence":"additional","affiliation":[{"name":"Medical Laboratory, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuo","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Medical Laboratory, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojun","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Yu","sequence":"additional","affiliation":[{"name":"Medical Laboratory, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[{"name":"Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Feng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China;"},{"name":"Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Boren Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2020013012001448100_B1","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"2020013012001448100_B2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020013012001448100_B3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"16","key":"2020013012001448100_B4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2020013012001448100_B5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9967","key":"2020013012001448100_B6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2020013012001448100_B7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-019-0705-x","article-title":"Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2020013012001448100_B8","doi-asserted-by":"crossref","unstructured":"Gardner\n              R\n            , AnnesleyC, FinneyO, et al. Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia [abstract]. Blood. 2018;132(suppl 1). Abstract 278.","DOI":"10.1182\/blood-2018-99-113126"},{"issue":"suppl 1","key":"2020013012001448100_B9","article-title":"A feasibility and safety study of CD19 and CD22 chimeric antigen receptors-modified T cell cocktail for therapy of B cell acute lymphoblastic leukemia [abstract]","volume":"132","author":"Yang","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020013012001448100_B10","article-title":"CAR22\/ 19 cocktail therapy for patients with refractory\/relapsed B-cell malignancies. [abstract]","volume":"132","author":"Huang","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020013012001448100_B11","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia [abstract]","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020013012001448100_B12","article-title":"Phase 1 study of CD19\/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL) [abstract]","volume":"132","author":"Schultz","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020013012001448100_B13","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2020013012001448100_B14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"2020013012001448100_B15","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2020013012001448100_B16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"2020013012001448100_B17","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/5\/387\/1632887\/bloodbld2019003293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/5\/387\/1632887\/bloodbld2019003293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T12:01:52Z","timestamp":1580385712000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/5\/387\/428752\/Sequential-CD1922-CAR-T-therapy-induces-sustained"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,1,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003293","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}